Propanc Biopharma Establishes $100 Million Crypto Treasury to Fuel Cancer Therapy Development

Australian biotech firm Propanc Biopharma has taken a significant step into the world of digital assets by establishing a cryptocurrency treasury. The company secured up to $100 million in funding from Hexstone Capital, a crypto-focused family office, through a private placement structured as convertible preferred stock. This investment will be used to develop a digital asset treasury and accelerate the development of its lead cancer therapy, PRP. Propanc aims to initiate first-in-human trials for PRP in the second half of 2026.